Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-20

Last Posted Date: 2009-05-01

Lead Sponsor: Sanofi

Target Recruit Count: 168

Registration Number: NCT00087958

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: gemcitabine/Eloxatin (GEMOX)
Drug: carboplatin/paclitaxel (CP)

First Posted Date: 2004-07-16

Last Posted Date: 2009-04-16

Lead Sponsor: Sanofi

Target Recruit Count: 383

Registration Number: NCT00087802

Locations: 🇺🇸
Dayton Oncology & Hematology, P.A., Kettering, Ohio, United States
🇺🇸
Interlakes Oncology & Hematology, P.C., Rochester, New York, United States
🇺🇸
Florida Cancer Institute, New Port Richey, Florida, United States

and more 56 locations

Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Metastases

First Posted Date: 2004-04-22

Last Posted Date: 2008-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 438

Registration Number: NCT00081796

Locations: 🇨🇱
Las Condes, Santiago, Chile

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

Phase 2

Completed

Conditions: Percutaneous Coronary Intervention

First Posted Date: 2004-02-18

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 3532

Registration Number: NCT00077844

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

First Posted Date: 2004-02-16

Last Posted Date: 2014-01-06

Lead Sponsor: Sanofi

Registration Number: NCT00008281

Locations: 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
Medical Oncology Internal Medicine, Los Angeles, California, United States

and more 129 locations

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

Phase 4

Completed

Conditions: Acute Ischemic Stroke

First Posted Date: 2004-02-16

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Registration Number: NCT00077805

Locations: 🇹🇷
Sanofi-Aventis, Istanbul, Turkey

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

Phase 4

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2004-02-16

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 4726

Registration Number: NCT00077753

Locations: 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-02-16

Last Posted Date: 2013-08-02

Lead Sponsor: Sanofi

Registration Number: NCT00017459

Locations: 🇺🇸
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States

and more 39 locations

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

Phase 3

Completed

Conditions: Myocardial Infarction
Acute ST-Segment Elevation

First Posted Date: 2004-02-16

Last Posted Date: 2009-04-20

Lead Sponsor: Sanofi

Target Recruit Count: 20506

Registration Number: NCT00077792

Locations: 🇦🇷
sanofi-aventis administrative Office, Buenos Aires, Argentina
🇫🇷
Sanofi- Aventis Administrative Office, Paris, France
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia

and more 2 locations

Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)

Phase 4

Completed

Conditions: Acute Coronary Syndrome

First Posted Date: 2004-02-16

Last Posted Date: 2009-10-15

Lead Sponsor: Sanofi

Registration Number: NCT00077818

Home Terms & Conditions Privacy Policy